Andres Allen M, Hernandez Genaro, Lee Pamela, Huang Chengqun, Ratliff Eric P, Sin Jon, Thornton Christine A, Damasco Marichris V, Gottlieb Roberta A
Donald P. Shiley BioScience Center, San Diego State University , San Diego, California.
Antioxid Redox Signal. 2014 Nov 10;21(14):1960-73. doi: 10.1089/ars.2013.5416. Epub 2013 Sep 20.
We have shown that autophagy and mitophagy are required for preconditioning. While statin's cardioprotective effects are well known, the role of autophagy/mitophagy in statin-mediated cardioprotection is not. In this study, we used HL-1 cardiomyocytes and mice subjected to ischemia/reperfusion to elucidate the mechanism of statin-mediated cardioprotection.
HL-1 cardiomyocytes exposed to simvastatin for 24 h exhibited diminished protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling, increased activation of unc-51-like kinase 1, and upregulation of autophagy and mitophagy. Similar findings were obtained in hearts of mice given simvastatin. Mevalonate abolished simvastatin's effects on Akt/mTOR signaling and autophagy induction in HL-1 cells, indicating that the effects are mediated through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Simvastatin-treated HL-1 cells exhibited mitochondrial translocation of Parkin and p62/SQSTM1, fission, and mitophagy. Because Parkin is required for mitophagy and is expressed in heart, we investigated the effect of simvastatin on infarct size in Parkin knockout mice. Simvastatin reduced infarct size in wild-type mice but showed no benefit in Parkin knockout mice. Inhibition of HMG-CoA reductase limits mevalonate availability for both cholesterol and coenzyme Q10 (CoQ) biosynthesis. CoQ supplementation had no effect on statin-induced Akt/mTOR dephosphorylation or macroautophagy in HL-1 cells, but it potently blocked mitophagy. Importantly, CoQ supplementation abolished statin-mediated cardioprotection in vivo.
Acute simvastatin treatment suppresses mTOR signaling and triggers Parkin-dependent mitophagy, the latter which is required for cardioprotection. Coadministration of CoQ with simvastatin impairs mitophagy and cardioprotection. These results raise the concern that CoQ may interfere with anti-ischemic benefits of statins mediated through stimulation of mitophagy.
我们已经表明自噬和线粒体自噬是预处理所必需的。虽然他汀类药物的心脏保护作用是众所周知的,但自噬/线粒体自噬在他汀类药物介导的心脏保护中的作用却并非如此。在本研究中,我们使用HL-1心肌细胞和遭受缺血/再灌注的小鼠来阐明他汀类药物介导的心脏保护机制。
暴露于辛伐他汀24小时的HL-1心肌细胞表现出蛋白激酶B(Akt)/雷帕霉素哺乳动物靶标(mTOR)信号传导减弱、unc-51样激酶1的激活增加以及自噬和线粒体自噬上调。在给予辛伐他汀的小鼠心脏中也获得了类似的结果。甲羟戊酸消除了辛伐他汀对HL-1细胞中Akt/mTOR信号传导和自噬诱导的影响,表明这些影响是通过抑制3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶介导的。辛伐他汀处理的HL-1细胞表现出Parkin和p62/SQSTM1的线粒体易位、裂变和线粒体自噬。由于Parkin是线粒体自噬所必需的且在心脏中表达,我们研究了辛伐他汀对Parkin基因敲除小鼠梗死面积的影响。辛伐他汀减小了野生型小鼠的梗死面积,但在Parkin基因敲除小鼠中没有益处。HMG-CoA还原酶的抑制限制了甲羟戊酸用于胆固醇和辅酶Q10(CoQ)生物合成。CoQ补充对HL-1细胞中他汀类药物诱导的Akt/mTOR去磷酸化或巨自噬没有影响,但它有效地阻断了线粒体自噬。重要的是,CoQ补充消除了体内他汀类药物介导的心脏保护作用。
急性辛伐他汀治疗抑制mTOR信号传导并触发Parkin依赖性线粒体自噬,后者是心脏保护所必需的。CoQ与辛伐他汀共同给药会损害线粒体自噬和心脏保护作用。这些结果引发了人们对CoQ可能干扰通过刺激线粒体自噬介导的他汀类药物抗缺血益处的担忧。